Obesity drug DA-1726 tested in humans for first time
Disease control
Recruiting now
This early-stage trial tests a new drug called DA-1726 in 139 people with obesity. The main goal is to check safety and side effects. Researchers will also measure how the drug moves through the body and its effect on weight. Participants receive either the drug or a placebo, and…
Phase: PHASE1 • Sponsor: NeuroBo Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC